SCHEMBL2336447

SCHEMBL2336447

COc1ccc(O)c(S(=O)(=O)O)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 1/20 0.50
MPL P40238 1/20 0.50
HPGD P15428 3/20 0.49
HSD17B10 Q99714 2/20 0.49
LMNA P02545 1/20 0.49
HIF1A Q16665 1/20 0.49
ALDH1A1 P00352 3/20 0.48
GAA P10253 3/20 0.48
KDM4E B2RXH2 2/20 0.48
MEN1 O00255 2/20 0.48
MAPT P10636 2/20 0.48
KMT2A Q03164 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
THRB P10828 1/20 0.48
RECQL P46063 1/20 0.48
BLM P54132 1/20 0.48
MCL1 Q07820 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10785102 0.98 MPL (0.49) ERN1MPLHPGDHSD17B10LMNA
SCHEMBL6859803 0.85 ERN1 (0.50) ERN1HPGDHSD17B10ALDH1A1GAA
SCHEMBL28873749 0.85 KDM4E (0.53) ERN1ALDH1A1GAAKDM4EMEN1
SCHEMBL1155621 0.85 NPC1 (0.52) ERN1MPLHPGDLMNAHIF1A
SCHEMBL10785081 0.81 PTGS1 (0.55) ERN1HPGDHSD17B10ALDH1A1GAA
SCHEMBL9154234 0.81 MPL (0.54) ERN1MPLHPGDHSD17B10LMNA
SCHEMBL30965843 0.81 L3MBTL1 (0.64) LMNAALDH1A1GAAMAPTKMT2A
SCHEMBL668653 0.81 L3MBTL1 (0.64) LMNAALDH1A1GAAMAPTKMT2A
SCHEMBL8300776 0.81 POLB (0.49) MPLHPGDLMNAALDH1A1GAA
SCHEMBL343614 0.80 CYP3A4 (0.51) HPGDHSD17B10LMNAHIF1AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2358655-B1 METHOD FOR PRODUCING PHENOL AND ACETONE SABIC INNOVATIVE PLASTICS IP (NL) 2015-05-06 EP claimed
US-8030525-B2 Method for producing phenol and acetone SABIC INNOVATIVE PLASTICS IP B.V. (NL) 2011-10-04 US claimed
EP-2358655-A1 METHOD FOR PRODUCING PHENOL AND ACETONE SABIC Innovative Plastics IP B.V. (NL) 2011-08-24 EP claimed
US-20100099919-A1 METHOD FOR PRODUCING PHENOL AND ACETONE SABIC INNOVATIVE PLASTICS IP B.V. (NL) 2010-04-22 US claimed
WO-2010045423-A1 METHOD FOR PRODUCING PHENOL AND ACETONE SABIC INNOVATIVE PLASTICS IP B.V. (NL) 2010-04-22 WO claimed
US-6783913-B2 POLYMERIC ACETAL RESIN CONTAINS UNITS (A), (B), (C), (D), AND (E). UNIT (A) IS A VINYL ALCOHOL UNIT. UNIT; (B) IS A POLYVINYL ACETAL UNIT CONTAINING AN R GROUP, WHERE R IS HYDROGEN, AN ALIPHATIC GROUP, AN AROMATIC GROUP, OR AN KODAK POLYCHROME GRAPHICS LLC 2004-08-31 US claimed
US-20030198887-A1 Polymeric acetal resins containing free radical inhibitors and their use in lithographic printing EASTMAN KODAK COMPANY 2003-10-23 US claimed
US-4910021-A Oral administered coated capsule for colonic absorption R. P. SCHERER CORPORATION (US) 1990-03-20 US claimed
EP-0036534-B1 AN ORALLY ADMINISTRABLE DRUG FORM COMPRISING A BETA-LACTAM ANTIBIOTIC AND AN ADJUVANT INTERx RESEARCH CORPORATION (US) 1987-09-23 EP claimed
EP-0225189-A2 Targeted enteral delivery system R.P. SCHERER CORPORATION (US) 1987-06-10 EP claimed
US-4470980-A Method of increasing oral absorption of β-lactam antibiotics INTERX RESEARCH CORP. (US) 1984-09-11 US claimed
US-4406896-A ANTIBIOTICS, ACIDS, HYDROXY MERCK & CO., INC. (US) 1983-09-27 US claimed
EP-0036534-A1 An orally administrable drug form comprising a beta-lactam antibiotic and an adjuvant INTERx RESEARCH CORPORATION (US) 1981-09-30 EP claimed
EP-0036145-A1 An orally administered drug form comprising a polar bioactive agent and an adjuvant INTERx RESEARCH CORPORATION (US) 1981-09-23 EP claimed
EP-0035770-A2 An orally administered drug form comprising a glycosidic antibiotic and an adjuvant INTERx RESEARCH CORPORATION (US) 1981-09-16 EP claimed
EP-0031561-A2 A rectally administered suppository comprising a drug and an adjuvant MERCK & CO. INC. (US) 1981-07-08 EP claimed
CN-117263783-A Method for preparing acetone by oxidation of isoparaffin 中国石油大学(华东) 2023-12-22 CN disclosed
CN-117258787-A Catalyst for preparing acetone by oxidation of isoparaffin and preparation method thereof 中国石油大学(华东) 2023-12-22 CN disclosed
EP-0035770-A2 An orally administered drug form comprising a glycosidic antibiotic and an adjuvant INTERx RESEARCH CORPORATION (US) 1981-09-16 EP disclosed
EP-0031561-A2 A rectally administered suppository comprising a drug and an adjuvant MERCK & CO. INC. (US) 1981-07-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099919-A1 METHOD FOR PRODUCING PHENOL AND ACETONE HAO2, AOX1, HPD ERN1 3107/4885MPL 2034/4885HPGD 165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.